Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

Jt, Thigpen; Blessing, J A; Homesley, Howard D.; Wt, Creasman; Sutton, Gregory P.

doi:10.1016/0020-7292(89)90346-9

Cited by 21 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The chemosensitivity results of MiCK were compatible with GOG clinical trial findings. [13][14][15][16][17][18][19] GOG trials indicate most patients are best treated with combination chemotherapy. In this study, although based on wide confidence intervals because of the small number of samples, the results indicate that 25% of patients might be treated with single agent chemotherapy selected by the MiCK assay.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment

et al. 2010

View full text Add to dashboard Cite

Objective:The in vitro microculture kinetic (MiCK) apoptosis assay has been used to predict single or combination chemotherapy response in leukemia patients. This feasibility study addressed MiCK in endometrial cancer specimens. Methods: Endometrial cancer specimens from total abdominal hysterectomies were processed at a central laboratory. Single cell suspensions of viable endometrial cancer cells were plated in individual wells. Single and combination regimens were tested: combinations of doxorubicin, cisplatin, and paclitaxel and carboplatin and paclitaxel (Gynecologic Oncology Group [GOG] 209 endometrial cancer phase III trial arms) as well as single agent testing with paclitaxel, carboplatin, doxorubicin, cisplatin, ifosfamide, and vincristine (active agents in GOG trials). Apoptosis was measured continuously over 48 hours. Results: Fifteen of nineteen patients had successful assays. The highest mean chemo sensitivity was noted in the combination of cisplatin, doxorubicin, and paclitaxel with lower mean chemosensitivity for carboplatin and paclitaxel. Combination chemotherapy had higher chemosensitivity than single drug chemotherapy. However, in 25% of patients a single drug had higher chemosensitivity than combination chemotherapy. As single agents, ifosfamide, cisplatin, and paclitaxel had the highest kinetic unit values. Conclusion: Using a panel of agents simulating clinical dose regimens, the MiCK assay was feasible in evaluating in vitro chemosensitivity of endometrial cancer. MiCK assay results correlated with GOG clinical trial results. However, 25% of patients might be best treated with single agent chemotherapy selected by MiCK. Ifosfamide, cisplatin, and paclitaxel appear to have high activity as single agents. MiCK may be useful in future new drug testing and individualizing endometrial cancer patient's chemotherapy management.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[13][14][15][16][17][18][19] There was a high correlation between the demonstrated activity of chemotherapy drugs in vivo in multi-institutional trials and the chemosensitivity of patients' cancer cells in the MiCK assay (Pearson's correlation of 0.85, p＜0.0328).…”

mentioning

confidence: 98%

Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Forty-nine patients with advanced or recurrent endometrial carcinoma were treated with cisplatin 50 mg/m 2 i.v. every 3 weeks [48]. Of these patients, 10 (20%) achieved an OR, including 2 (4%) CRs.…”

Section: Chemotherapy Treatment Of Recurrent Endometrial Cancermentioning

confidence: 98%

“…Several agents have been investigated in the treatment of advanced or recurrent endometrial carcinoma (Table 3) [47][48][49][50][51][52][53]. One of the first cytotoxic agents investigated was doxorubicin.…”

Section: Chemotherapy Treatment Of Recurrent Endometrial Cancermentioning

confidence: 99%

Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan

Fiorica

2002

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Currently, no standard chemotherapy regimen for endometrial cancer exists, but single-agent doxorubicin is active, with responses observed in up to one-third of previously untreated patients (Moore et al, 1991). Other single agents with modest activity include cisplatin (Thigpen et al, 1984a(Thigpen et al, , 1989 and carboplatin (van Wijk et al, 2003). Although the response rates with the combination doxorubicinÀcisplatin appear to be higher than those achieved with either agent alone, there is no evidence that survival is any longer with combination therapy.…”

mentioning

confidence: 99%

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

et al. 2005

View full text Add to dashboard Cite

The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status p2 entered the study. Docetaxel 70 mg m À2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39 -74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1 -50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3 -4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

show abstract

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

Cited by 21 publications

References 0 publications

Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment

Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment

Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

Contact Info

Product

Resources

About